ArticleiScience2026
Cancer cell-intrinsic rewiring of the colorectal cancer secretome.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Secreted factors are essential mediators of cellular communication that are exploited by tumors to control their environment and evade immune attack. However, how cancer cells rewire their secretome is unclear due to challenges in reliably profiling cancer cell-specific secreted factors. Here, we apply a click chemistry-based approach to selectively profile the secretome of patient-derived colorectal cancer (CRC) and healthy colon organoids. We observe cancer cell-intrinsic rewiring of the secretome during malignancy, with clear separation between microsatellite stable (MSS) and instable cancers. We then leverage this secretomics dataset to identify secreted factors that mark immune-excluded cancers, revealing NOTUM as a marker of decreased T cell infiltration across four independent datasets. Overall, our study provides an in-depth characterization of the cancer cell-intrinsic secretome of MSS-CRC and nominates NOTUM as a secreted factor marking immune-excluded colorectal cancers. This provides a scalable framework to link cancer cell-derived secreted factors to relevant tumor phenotypes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.